-
Mashup Score: 439
Nature Chemical Biology – A compound screen using zebrafish identified carbonic anhydrase (CA) as a modulator of tau toxicity. CA inhibition abrogates lysosomal acidification and causes tau…
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet
-
Mashup Score: 4
As monoclonal antibodies roll out, uncertainty about their risks and benefits is dividing physicians
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
As monoclonal antibodies roll out, uncertainty about their risks and benefits for #Alzheimers disease patients is dividing physicians. https://t.co/cAys8Xv4E9
-
-
Mashup Score: 435
Nature Chemical Biology – A compound screen using zebrafish identified carbonic anhydrase (CA) as a modulator of tau toxicity. CA inhibition abrogates lysosomal acidification and causes tau…
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet-
The unexpected potential for a glaucoma drug to be used to help prevent #Alzheimers disease https://t.co/Po3yJJoKGO
-
-
Mashup Score: 429
Nature Chemical Biology – A compound screen using zebrafish identified carbonic anhydrase (CA) as a modulator of tau toxicity. CA inhibition abrogates lysosomal acidification and causes tau…
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet-
The unexpected potential for a glaucoma drug to be used to help prevent #Alzheimers disease https://t.co/Po3yJJoKGO
-
-
Mashup Score: 4
As monoclonal antibodies roll out, uncertainty about their risks and benefits is dividing physicians
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
As monoclonal antibodies roll out, uncertainty about their risks and benefits for #Alzheimers disease patients is dividing physicians. https://t.co/cAys8Xv4E9
-
-
Mashup Score: 1824
INTRODUCTION Emerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegene…
Categories: General Medicine News, Expert PicksTweet-
A substantial reduction of #Alzheimers disease associated with semaglutide (Ozempic) in > 1 million people with Type 2 diabetes from a nationwide data resource https://t.co/0hQlGivUGi https://t.co/MDdsb4HcVc
-
-
Mashup Score: 1812
INTRODUCTION Emerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegene…
Categories: General Medicine News, Expert PicksTweet-
A substantial reduction of #Alzheimers disease associated with semaglutide (Ozempic) in > 1 million people with Type 2 diabetes from a nationwide data resource https://t.co/0hQlGivUGi https://t.co/MDdsb4HcVc
-
-
Mashup Score: 1758
INTRODUCTION Emerging preclinical evidence suggests that semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) for type 2 diabetes mellitus (T2DM) and obesity, protects against neurodegene…
Categories: General Medicine News, Expert PicksTweet-
A substantial reduction of #Alzheimers disease associated with semaglutide (Ozempic) in > 1 million people with Type 2 diabetes from a nationwide data resource https://t.co/0hQlGivUGi https://t.co/MDdsb4HcVc
-
-
Mashup Score: 5Company misled investors on possible Alzheimer’s drug, SEC charges - 1 month(s) ago
Agency fines Cassava $40 million, and two of its employees lesser amounts, over research on simufilam
Source: www.science.orgCategories: General Medicine News, Future of MedicineTweet-
The troubled biopharma company Cassava Sciences has agreed to pay $40 million to settle U.S. Securities and Exchange Commission charges that it had misled investors about early clinical results for its experimental #Alzheimers disease drug, simufilam. https://t.co/AF2GFNe81k
-
-
Mashup Score: 434Can flashing lights stall Alzheimer’s? What the science shows - 1 month(s) ago
Nature – Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.
Source: www.nature.comCategories: General Medicine News, Expert PicksTweet-
Can 40-hertz stimulation of the brain with both light and sound for 1 hour each day slow the progression of #Alzheimers disease? The results from a 600 participant randomized trial are pending A new @Nature feature by @ElieDolgin https://t.co/abkcDCbFIu https://t.co/NSazETGlYv
-
The unexpected potential for a glaucoma drug to be used to help prevent #Alzheimers disease https://t.co/Po3yJJoKGO